Floatz logo

Xeomin®

Spasticity, Muscle

Sisli Hamidiye Etfal Training and Research HospitalPhase 4 / ApprovedActive
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Spasticity, Muscle cohort.

Asset / SponsorPhaseRating
Meditoxin
Medy-Tox
Phase 4BB
Arbaclofen
RVL Pharmaceuticals, Inc.
Phase 3BB
ABOBOTULINUMTOXINA
Neurology Center of New England P.C.
Phase 3CCC
Bont A
Kayseri City Hospital
N/AD
AUTOLOGOUS CONDITIONED PLASMA
Ege University
N/AD

Same molecule, other indications

Xeomin® is also rated in:

Muscle SpasticityDormant
BBB
Indicative ·
79 / 100
View asset →
Migraine DisordersDormant
BBB
Indicative ·
77 / 100
View asset →
stroke disorderDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →